Transcenta is a clinical stage biopharmaceutical company that fully integrates antibody-based biotherapeutics discovery, research, development and manufacturing. On September 29, 2021, Transcenta was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 06628.
Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Beijing, Shanghai and Guangzhou in China and in Princeton, US, and External Partnering Center in Boston and Los Angeles, US. Transcenta is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.
For more information, please visit www.transcenta.com.
Company Details
- Employees
- 95
- Address
- Princeton, Us
- Phone
- 0571-28279502
- me****@****nta.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- transcenta.com
- HQ
- Princeton
Transcenta Questions
Transcenta's helpline number is 0571-28279502
Transcenta's website is transcenta.com
Transcenta's LinkedIn profile is https://www.linkedin.com/company/transcenta
Transcenta has
95 employees.
View email and phone details for 95
employees at Transcenta.
Transcenta's industry is
Biotechnology Research
Transcenta's top competitors are
Harbour Biomed,
Avenzo Therapeutics,
Remegen Biosciences,
Ascentage Pharma,
Hutchmed,
Agios Pharmaceuticals,
Wugen,
Cabaletta Bio,
Hengrui Pharma,
Hjb.
Transcenta's support email address is media@transcenta.com
Transcenta's categories are Biotechnology Research
